Physician profile
Parshaw Jonathan Dorriz
NPI 1972940625
$1,529,483.05
in general payments reported to CMS, 2019-2025
58 companies · $530K in 2025
The $530K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,424 · 2020: $3,066 · 2021: $62K · 2022: $203K · 2023: $351K · 2024: $372K · 2025: $530K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1.2M · Food and Beverage: $7,095 · Travel and Lodging: $3,291 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,242,029.87 |
| Food and Beverage | $7,095.37 |
| Travel and Lodging | $3,291.32 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ceribell, INC. | $1,519,113.76 | 2019-2025 | Pocket Eeg Device, Ceribell Rapid Response Eeg |
| Abbvie INC. | $2,563.93 | 2021-2025 | Qulipta, Botox, Ubrelvy |
| Ucb, INC. | $952.85 | 2019-2025 | Briviact, Fintepla, Nayzilam |
| Acadia Pharmaceuticals INC | $738.33 | 2021-2025 | Nuplazid, Daybue |
| Sk Life Science, INC. | $725.14 | 2020-2025 | |
| Biogen, INC. | $591.88 | 2019-2025 | Leqembi, Vumerity, Tysabri |
| Supernus Pharmaceuticals, INC. | $521.17 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $385.20 | 2019-2025 | Austedo Xr, Austedo Xr |
| Allergan, INC. | $310.34 | 2020-2021 | |
| Lundbeck LLC | $197.59 | 2019-2025 | Vyepti, Rexulti |
| Alexion Pharmaceuticals, INC. | $196.95 | 2021-2025 | Ultomiris |
| Lilly USA, LLC | $184.93 | 2019-2024 | Amyvid, Emgality, Kisunla |
| Biohaven Pharmaceuticals, INC. | $172.97 | 2020-2021 | |
| Argenx US, INC. | $166.89 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Adamas Pharmaceuticals, INC. | $142.67 | 2019-2020 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parshaw Dorriz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.